Published in N Engl J Med on December 06, 2014
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | NCT03336073
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia (2016) 1.43
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Treatment of relapsed multiple myeloma. N Engl J Med (2015) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood (2016) 1.06
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol (2015) 1.03
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol (2015) 1.00
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood (2016) 0.96
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood (2015) 0.95
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood (2015) 0.94
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits (2015) 0.88
New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J (2016) 0.87
Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol (2016) 0.87
The novel mechanism of lenalidomide activity. Blood (2015) 0.86
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia (2015) 0.83
Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res (2015) 0.83
Multiple myeloma cancer stem cells. Oncotarget (2016) 0.82
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant (2016) 0.82
Current therapeutic strategies for multiple myeloma. Int J Clin Oncol (2015) 0.81
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood (2016) 0.81
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol (2016) 0.81
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant (2016) 0.80
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood (2016) 0.80
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity. Case Rep Cardiol (2016) 0.80
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol (2016) 0.80
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood (2016) 0.79
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica (2015) 0.79
Progress and Paradigms in Multiple Myeloma. Clin Cancer Res (2016) 0.78
Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila) (2016) 0.78
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget (2017) 0.78
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant (2015) 0.78
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia (2016) 0.78
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Treatment of relapsed multiple myeloma. N Engl J Med (2015) 0.78
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clin Pharmacokinet (2017) 0.77
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia (2016) 0.77
Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol (2016) 0.77
Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines. J Pharmacol Exp Ther (2015) 0.77
Bortezomib and thalidomide maintenance after stem-cell transplantation for multiple myeloma: A PETHEMA/GEM trial. Leukemia (2017) 0.77
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother (2015) 0.76
Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma. P T (2016) 0.76
Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging (2016) 0.76
The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncol (2016) 0.76
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. J Hematol Oncol (2016) 0.76
Innovations in treatment and response evaluation in multiple myeloma. Haematologica (2016) 0.76
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther (2016) 0.76
Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma. Blood (2017) 0.75
Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res (2017) 0.75
Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol (2017) 0.75
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol (2016) 0.75
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol (2016) 0.75
Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists. Curr Oncol (2016) 0.75
Developments in the Field of Myeloma in the Last Decade. Indian J Hematol Blood Transfus (2017) 0.75
Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer (2016) 0.75
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J (2016) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. Oncoimmunology (2016) 0.75
The Danish National Multiple Myeloma Registry. Clin Epidemiol (2016) 0.75
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget (2016) 0.75
The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int (2016) 0.75
Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther (2017) 0.75
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther (2015) 0.75
Status Epilepticus and Blindness in a Patient with Carfilzomib-Associated Posterior Reversible Encephalopathy Syndrome. Cureus (2017) 0.75
Multiple myeloma: patient outcomes in real-world practice. Br J Haematol (2016) 0.75
Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J (2016) 0.75
Combination therapeutics in complex diseases. J Cell Mol Med (2016) 0.75
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep (2015) 0.75
Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J (2017) 0.75
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood (2017) 0.75
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biol Blood Marrow Transplant (2015) 0.75
Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med (2016) 0.75
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals. Am Health Drug Benefits (2016) 0.75
Haematological cancer: ASPIRE for unprecedented benefit with carfilzomib in MM. Nat Rev Clin Oncol (2014) 0.75
Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan. Cancer Sci (2017) 0.75
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J (2017) 0.75
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer (2016) 0.75
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma. Ther Adv Hematol (2016) 0.75
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer (2016) 0.75
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol (2017) 0.75
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma. Am Health Drug Benefits (2016) 0.75
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. PLoS One (2017) 0.75
Multiple myeloma cells capacity to decompose H2O2 determines lenalidomide sensitivity. Blood (2016) 0.75
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther (2016) 0.75
Emerging drugs and combinations to treat multiple myeloma. Oncotarget (2017) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia (2016) 0.75
Cancer and Heart Failure: Understanding the Intersection. Card Fail Rev (2017) 0.75
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals (Basel) (2017) 0.75
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol (2017) 0.75
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica (2017) 0.75
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol (2017) 0.75
A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood (2017) 0.75
Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Rep (2017) 0.75
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cell Oncol (Dordr) (2017) 0.75
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Exp Hematol Oncol (2017) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Multigait soft robot. Proc Natl Acad Sci U S A (2011) 3.57
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica (2007) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol (2013) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol (2008) 2.60
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Microsurgical keyhole approach for middle fossa arachnoid cyst fenestration. Neurosurgery (2003) 2.58